BTG Pactual Asset Management US LLC Trims Position in Royalty Pharma plc (NASDAQ:RPRX)

BTG Pactual Asset Management US LLC decreased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 88,584 shares of the biopharmaceutical company’s stock after selling 2,357 shares during the quarter. BTG Pactual Asset Management US LLC’s holdings in Royalty Pharma were worth $2,362,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Norges Bank bought a new position in shares of Royalty Pharma in the 4th quarter valued at about $124,498,000. Swedbank AB lifted its holdings in shares of Royalty Pharma by 10.3% in the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after acquiring an additional 1,136,800 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Royalty Pharma in the fourth quarter worth about $19,990,000. New South Capital Management Inc. boosted its holdings in Royalty Pharma by 19.9% during the 4th quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company’s stock valued at $75,436,000 after acquiring an additional 490,754 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of Royalty Pharma by 32.0% during the fourth quarter. Russell Investments Group Ltd. now owns 1,855,791 shares of the biopharmaceutical company’s stock valued at $47,319,000 after purchasing an additional 449,551 shares during the period. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 2.4 %

NASDAQ RPRX opened at $31.95 on Friday. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.20. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The company has a market capitalization of $18.42 billion, a price-to-earnings ratio of 22.03, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. The company’s 50-day simple moving average is $32.50 and its two-hundred day simple moving average is $29.14.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Analysts Set New Price Targets

RPRX has been the subject of a number of research analyst reports. Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Royalty Pharma has an average rating of “Buy” and a consensus target price of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.